Short answer
Entrada Therapeutics, Inc. (TRDA) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $905,000 (down 43.9% year over year) with net income of −$40M.
Q3 2026 key financials · XBRL
- Revenue
- $905,000
- −43.9% YoY · +0.8% QoQ
- Net income
- −$40M
- +10.0% YoY · +7.1% QoQ
- Operating margin
- -4606.5%
- EPS (diluted)
- −$0.94
- +11.3% YoY · +6.9% QoQ
Source: XBRL data from the Entrada Therapeutics, Inc. (TRDA) Q3 2026 10-Q on SEC EDGAR. USD.
Entrada Therapeutics, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Collaboration revenue $0.9M, down $0.7M YoY from $1.6M
- Net loss $39.7M vs $44.1M YoY, operating loss $41.7M vs $47.1M
- ENTR-601-44 highest program spend at $6.2M, ENTR-601-45 increased to $4.5M
- Operating cash use $104.1M, marketable-securities maturities drove $124.9M investing inflow
- Cash, equivalents and securities $193.0M, funding expected into fourth quarter 2027; additional funding required
Risk Factors
- Newly added regulatory risk: October 2026 FDA orphan-drug designation for ENTR-601-45 may not deliver exclusivity or other benefits
- Most material regulatory update: June 2026 FDA draft guidance permits one pivotal trial with confirmatory evidence, but additional trials remain possible
- Compliance risk: BIOSECURE Act Section 851 could disrupt China-based suppliers and foreign contract manufacturers
- Operational risk: Vertex controls VX-670 development, with interim GALILEO Phase 1/2 results expected in second half of 2026
- Financial risk: Cash, equivalents and marketable securities fund operations into fourth quarter 2027, but substantial going-concern doubt remains
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Entrada Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.